Myriad Genetics, Inc. · NASDAQ:MYGN

Myriad Genetics — 42nd Annual J.P. Morgan Healthcare Conference 2024

34 slides from Myriad Genetics's conference presentation, Jan 16, 2024

1. Slide 1: 42nd Annual J.P. Morgan Healthcare Conference

   ©2024 Myriad Genetics, Inc. 42nd Annual J.P. Morgan Healthcare Conference J A N U A R Y 1 0 , 2 0 2 4 ©2024 Myriad Genetics, Inc.

2. Slide 2: Forward-looking statements and Non-GAAP financial measures

   ©2024 Myriad Genetics, Inc. Some of the information presented here today contains projections or other forward-looking statements regarding future events or the future financial performance of the Company. FORWARD-LOOKING STATEMENTS AND DISCLAIMERS These statements are based on management’s current

3. Slide 3: Moving from transformation to innovation and growth

   ©2024 Myriad Genetics, Inc. Moving from transformation to innovation and growth Revealing the power of genetic science – for everyone Mission We advance health and well-being for all, empowering every individual by revealing the answers inside each of us. Vision As a leader in genetic testing and pr

4. Slide 4: Myriad Genetics at-a-glance

   ©2024 Myriad Genetics, Inc. Myriad Genetics at-a-glance 45,000+ active ordering healthcare providers1 10%+ annual revenue growth for fourth consecutive quarter3 Commercial execution driving volume growth; price stability A leader in genetic testing Established franchises in hereditary cancer, pharma

5. Slide 5: Pillars of long-term growth and profitability

   ©2024 Myriad Genetics, Inc. Top-tier science delivering products that are clinically validated and demonstrate proven utility (quality, access and cost) in real world clinical settings Automated, scalable and cost- effective laboratory operations and technology platform Strong digitally enabled comm

6. Slide 6: Focus areas: Oncology, Women's Health and Pharmacogenomics

   ©2024 Myriad Genetics, Inc. 3 focus areas: Oncology, Women's Health and Pharmacogenomics Using genetic insights to help physicians understand how genetic alterations impact patient response to antidepressants and other drugs. Psychiatrist Primary Care Nurse Practitioner/Physician Assistant $5 Billio

7. Slide 7: Diversified portfolio within large, fragmented, actionable markets

   ©2024 Myriad Genetics, Inc. Oncology Women’s Health PGx AFFECTED HCT + GERMLINE TUMOR PROFILING3 MRD HRD2 UROLOGY PRENATAL UNAFFECTED HCT PGx Actionable Market Opp.1 $1.2B $500M $20B+ $350M $600M $2.3B $3B $5B Market Penetration ~65% ~45% <5% ~40% ~35% ~50% <15% ~15% Myriad Products Diversified port

8. Slide 8: MyRisk addresses the needs of large and growing markets

   ©2024 Myriad Genetics, Inc. MyRisk addresses the needs of large and growing markets **Expected ***In cancers of focus Unaffected Market – Hereditary Screening Affected Market – Germline Screening TOTAL U.S. POPULATION ~332M TOTAL U.S. POPULATION WHO WOULD QUALIFY FOR HCT ~50M* TOTAL NUMBER OF WOMEN

9. Slide 9: Significant opportunity to accelerate MyRisk growth

   ©2024 Myriad Genetics, Inc. 55 65 Q3 '22 Q4 '22 Q1 '23 Q2 '23 Q3 '23 +24% +20% +18% +16% YOY Growth +4% Significant opportunity to accelerate MyRisk growth across Women’s Health, Imaging, Oncology and Urology Figures in thousands MyRisk patient portal MyRisk Medical Management Tool Enhancements Risk

10. Slide 10: GeneSight is the market-leading PGx test

    ©2024 Myriad Genetics, Inc. GeneSight is the market-leading PGx test helping address the Nation’s mental health crisis Ordered by tens of thousands of clinicians to inform medication selection and dosing GeneSight designed to help physicians understand how patients will respond to medications used t

11. Slide 11: GeneSight test volume growth and roadmap

    ©2024 Myriad Genetics, Inc. 85 95 105 115 125 Q3 '22 Q4 '22 Q1 '23 Q2 '23 Q3 '23 +31% +23% +19% +22% YOY Growth +34% Roadmap of expected highlights 2024 2025 Strong commercial execution driving significant volume growth in the last twelve months Health Economic Outcome Research (HEOR) study*** Signi

12. Slide 12: Prolaris designed to help determine optimal treatment planning

    ©2024 Myriad Genetics, Inc. Prolaris designed to help determine optimal treatment planning for patients with localized prostate cancer Prolaris utilizes two validated thresholds to identify men that are: • Safe for active surveillance (low-risk patients) • Candidates for a singular type of therapy (

13. Slide 13: Strong runway for Prolaris

    ©2024 Myriad Genetics, Inc. 5 6 7 8 Q3 '22 Q4 '22 Q1 '23 Q2 '23 Q3 '23 +22% +13% +9% +17% YOY Growth +15% 2024 2025 Expanded coverage from UnitedHealthcare ARR (Absolute Risk Reduction) report Publish 3-yr Metastasis study Prolaris Post-RP launch Actionable market size (US only)* Market penetration*

14. Slide 14: Comprehensive prenatal care with differentiated products

    ©2024 Myriad Genetics, Inc. Comprehensive prenatal care with differentiated products and reliable technology Shown to deliver accurate answers to patients regardless of age, ancestry, or body mass index—the Prequel Prenatal Screen with AMPLIFYTM helps determine a pregnancy’s risk for a variety of ch

15. Slide 15: Prenatal market continues to grow

    ©2024 Myriad Genetics, Inc. 80 85 90 95 100 105 Q3 '22 Q4 '22 Q1 '23 Q2 '23 Q3 '23 +12% +12% +20% (1%) YOY Growth 0% 2024 Actionable market size (US only)* Market penetration* Market growth** MYGN market share* ~$1.3B 45-55% Low single digits Low-to-mid teens ~$950M 40-50% Low single digits Mid teen

16. Slide 16: Operational highlights fueling our growth

    ©2024 Myriad Genetics, Inc. Operational highlights fueling our growth Team Engagement Market Perception and Customer Service Levels Efficiency & Speed Revenue Cycle All data as of September 30, 2023 except as otherwise noted * SOURCE: 2022 survey conducted by Edelman HCP ETM Pulse 2022. Next time yo

17. Slide 17: Enterprise infrastructure and capability investments

    ©2024 Myriad Genetics, Inc. $80M* investment in modern labs $12M annual savings starting in 2025 Enterprise infrastructure and capability investments 17 2022 2023 2024 2025 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 NovaSeq Transitions Whole Exome New Facility Construction Shift Operations to N

18. Slide 18: Product roadmap summary

    ©2024 Myriad Genetics, Inc. 2023 2024 2025 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Product roadmap summary Foresight Universal Plus Prolaris Post RP Pathology AI (discovery) Validation 2H Indication Expansion (e.g. Breast and Prostate) 2H Study Full Launch 4Q Tyrer-Cuzick v8 3Q MyRisk Panel expansion 1Q

19. Slide 19: Active pipeline to better serve patients and providers

    ©2024 Myriad Genetics, Inc. Active pipeline to better serve patients and providers What is It? Integrated assay for NIPS + carrier screen + fetal recessive status + feto- maternal blood compatibility on a single blood draw on one person Key advantages • Faster turnaround time • 3x lower cost of good

20. Slide 20: FirstGene: Transformative prenatal screen running multiple tests at once

    ©2024 Myriad Genetics, Inc. FirstGene: Transformative prenatal screen running multiple tests at once 20 Providers don’t have enough time to talk about genetics Current PROBLEMS with prenatal genetic screening Only 50% utilization of carrier screening Only 30% of fathers get screened when mother is a

21. Slide 21: Oncology: Expanding breadth of portfolio

    ©2024 Myriad Genetics, Inc. Oncology: Expanding breadth of portfolio addressing real-world community needs 21 Therapeutic Selection Prognostic Testing Surgical Decisions High Risk Screening Planned Product Expansion Measurable Residual Disease Monitoring Recurrence Treatment Selection & Clinical Tri

22. Slide 22: High-definition MRD: Differentiation built upon existing competencies

    ©2024 Myriad Genetics, Inc. High-definition MRD: Differentiation built upon existing competencies 22 Detect presence or absence of tumor cfDNA Comparable Myriad test TM Tumor + normal sample prep and sequencing Bioinformatic identification of somatic variants cfDNA isolation and targeted sequencing

23. Slide 23: Precise MRD: Partnerships with world-leading collaborators

    ©2024 Myriad Genetics, Inc. Precise MRD: Partnerships with world-leading collaborators We anticipate the MRD test from Myriad will be more sensitive and specific than many other ctDNA offerings for monitoring the response and, therefore, may more accurately identify the patients who will or will not

24. Slide 24: Financial Highlights

    ©2024 Myriad Genetics, Inc. 24 Financial Highlights

25. Slide 25: 2023 revenue, adjusted gross margin, adjusted opex and adjusted EPS by quarter

    ©2024 Myriad Genetics, Inc. 10% points 181.2 183.5 191.9 $155 $195 Q1 '23 Q2 '23 Q3 '23 Q4 '23E 2023 revenue, adjusted gross margin, adjusted opex and adjusted EPS by quarter 25 144.5 133.4 137.3 $115 $145 Q1 '23 Q2 '23 Q3 '23 Q4 '23E (0.21) (0.08) (0.03) ($0.24) $0.00 Q1 '23 Q2 '23 Q3 '23 Q4 '23E A

26. Slide 26: 2023 Financial Guidance

    ©2024 Myriad Genetics, Inc. 2023 FINANCIAL GUIDANCE 2023 COMMENTS 2024 - 2026 COMMENTARY ADDITIONAL COMMENTS Total revenue $747 - $753 2023 annual growth between 10% - 11% over 2022. 10%+ CAGR Target total revenue of over $1 billion in 2026. This revenue target includes modest contribution from plan

27. Slide 27: Increased financial flexibility

    ©2024 Myriad Genetics, Inc. Increased financial flexibility; On-track to achieve positive adjusted operating cash flow in Q4 ‘23 27 Total cash and cash equivalents at end of third quarter of 2023* $86.3 Amount available to draw under the asset-based credit facility** 28.2 Net proceeds from follow-on

28. Slide 28: Revenue growth expected to accelerate 10%+ in '24-'26

    ©2024 Myriad Genetics, Inc. Revenue growth expected to accelerate 10%+ in ‘24–‘26 Right to win with core products driving market share gains Pipeline addresses large growth markets Operating leverage, profitability, and positive cash flow Capital deployment Provided 2024 full-year revenue guidance o

29. Slide 29: Q&A

    ©2024 Myriad Genetics, Inc. 29 Q&A

30. Slide 30: Appendix

    ©2024 Myriad Genetics, Inc. 30 Appendix

31. Slide 31: Reconciliation of GAAP to Non-GAAP Financial Measures

    ©2024 Myriad Genetics, Inc. Reconciliation of GAAP to Non-GAAP Financial Measures for the Three and Nine Months ended September 30, 2023 and 2022 31 (unaudited data in millions, except per share amounts)

32. Slide 32: Reconciliation of GAAP to Non-GAAP Financial Measures

    ©2024 Myriad Genetics, Inc. 32 (unaudited data in millions, except per share amounts) Reconciliation of GAAP to Non-GAAP Financial Measures for the Three and Nine Months ended September 30, 2023 and 2022

33. Slide 33: Reconciliation of GAAP to Non-GAAP Financial Measures

    ©2024 Myriad Genetics, Inc. 33 (unaudited data in millions, except per share amounts) Reconciliation of GAAP to Non-GAAP Financial Measures for the Three and Nine Months ended September 30, 2023 and 2022

34. Slide 34: Reconciliation of GAAP to Non-GAAP Financial Measures

    ©2024 Myriad Genetics, Inc. 34 (unaudited data in millions, except per share amounts) Reconciliation of GAAP to Non-GAAP Financial Measures for the Three and Nine Months ended September 30, 2023 and 2022

Myriad Genetics — 42nd Annual J.P. Morgan Healthcare Conference 2024 on 6ix